Even with the advent of novel therapeutic approaches such as CAR T-cell therapy, MLL ALLs often rapidly relapse as acute myeloid leukemia (AML) [7], and thus, treatment of MLL ALL patients remains an unmet need. The gene discussed is KMT2A; the disease is acute myeloid leukemia.